Semler Scientific, Inc. (OTCMKTS:SMLR) CEO Douglas Murphy-Chutorian Sells 1,250 Shares

Semler Scientific, Inc. (OTCMKTS:SMLR) CEO Douglas Murphy-Chutorian sold 1,250 shares of the stock in a transaction that occurred on Monday, October 11th. The shares were sold at an average price of $129.01, for a total value of $161,262.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Douglas Murphy-Chutorian also recently made the following trade(s):

  • On Monday, October 4th, Douglas Murphy-Chutorian sold 1,250 shares of Semler Scientific stock. The shares were sold at an average price of $127.28, for a total value of $159,100.00.

OTCMKTS:SMLR opened at $136.65 on Thursday. The firm has a market capitalization of $922.93 million, a price-to-earnings ratio of 50.61, a PEG ratio of 1.52 and a beta of 0.85. Semler Scientific, Inc. has a 1 year low of $52.90 and a 1 year high of $144.87. The business has a 50 day simple moving average of $114.62 and a 200-day simple moving average of $112.95.

Semler Scientific (OTCMKTS:SMLR) last issued its quarterly earnings results on Sunday, August 1st. The medical equipment provider reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.22. Semler Scientific had a return on equity of 68.78% and a net margin of 43.39%. The firm had revenue of $14.31 million for the quarter, compared to the consensus estimate of $14.53 million. On average, analysts expect that Semler Scientific, Inc. will post 2.82 earnings per share for the current year.

SMLR has been the subject of a number of research reports. Colliers Securities reissued an “average” rating and set a $151.00 price target on shares of Semler Scientific in a research note on Tuesday, September 28th. Zacks Investment Research lowered Semler Scientific from a “buy” rating to a “hold” rating in a research note on Thursday, October 7th. TheStreet raised Semler Scientific from a “d-” rating to an “a-” rating in a research note on Tuesday, September 28th. Lake Street Capital raised their price objective on Semler Scientific from $150.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 28th. Finally, B. Riley reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Semler Scientific in a research note on Wednesday, August 4th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $157.75.

Semler Scientific Company Profile

Semler Scientific, Inc engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests.

Featured Story: What are the advantages of the Stochastic Momentum Index?

Insider Buying and Selling by Quarter for Semler Scientific (OTCMKTS:SMLR)

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.